Loading…

Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?

Selenium is an essential trace element for humans, playing an important role in various major metabolic pathways. Selenium helps to protect the body from the poisonous effects of heavy metals and other harmful substances. Medical studies have provided evidence of selenium supplementation in preventi...

Full description

Saved in:
Bibliographic Details
Published in:Mutagenesis 2013-11, Vol.28 (6), p.625-629
Main Authors: Gupta, Satish, Jaworska-Bieniek, Katarzyna, Lubiński, Jan, Jakubowska, Anna
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3
cites cdi_FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3
container_end_page 629
container_issue 6
container_start_page 625
container_title Mutagenesis
container_volume 28
creator Gupta, Satish
Jaworska-Bieniek, Katarzyna
Lubiński, Jan
Jakubowska, Anna
description Selenium is an essential trace element for humans, playing an important role in various major metabolic pathways. Selenium helps to protect the body from the poisonous effects of heavy metals and other harmful substances. Medical studies have provided evidence of selenium supplementation in preventing certain cancers. Low and too high selenium (Se) status correlates with increased risk of e.g. lung, larynx, colorectal and prostate cancers. A higher level of selenium and supplementation with selenium has been shown to be associated with substantially reduced cancer mortality. Selenium exerts its biological roles through selenoproteins, which are involved in oxidoreductions, redox signalling, antioxidant defence, thyroid hormone metabolism and immune responses. Checkpoint kinase 2 (CHEK2) is an important signal transducer of cellular responses to DNA damage and acts as a tumour suppressor gene. Mutations in the CHEK2 gene have been shown to be associated with increased risks of several cancers. Four common mutations in CHEK2 gene (1100delC, IVS2+1G>A, del5395 and I157T) have been identified in the Polish population. Studies have provided evidence that CHEK2-truncating and/or missense mutations are associated with increased risk of breast, prostate, thyroid, colon and kidney cancers. The variability in penetrance and cancer expression in CHEK2 mutation carriers can probably be explained by the influence of other genetic or environmental factors. One of the possible candidates is Se, which together with genetic variations in selenoprotein genes may influence susceptibility to cancer risk.
doi_str_mv 10.1093/mutage/get050
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1492620453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/mutage/get050</oup_id><sourcerecordid>1492620453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3</originalsourceid><addsrcrecordid>eNqFkD1PwzAURS0EoqUwsiKPLKHP38mEUFQoohILzJGT2JUhiYudDPz7pkqBkek96R7dKx2ErgncEcjYsh16vTXLrelBwAmaEy55wlLgp2gOVKokZULN0EWMHwBEUQnnaEY5AQmg5miV6w5H05jODS0uDda49bWzzgTsLa50V41fcPETuw7n69ULxYfJ3vluTEMYwXh_ic6sbqK5Ot4Fen9cveXrZPP69Jw_bJKKiaxPjKrLkhOiM6ZLbtJaU8mrGkimKqtVSaxIpbSCq5pxRQkXlo2pyEpdp5RatkC3U-8u-K_BxL5oXaxM0-jO-CEWhGdUUuCCjWgyoVXwMQZji11wrQ7fBYHiYK6YzBWTuZG_OVYPZWvqX_pH1d-2H3b_dO0BInh35Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1492620453</pqid></control><display><type>article</type><title>Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?</title><source>Oxford Journals Online</source><creator>Gupta, Satish ; Jaworska-Bieniek, Katarzyna ; Lubiński, Jan ; Jakubowska, Anna</creator><creatorcontrib>Gupta, Satish ; Jaworska-Bieniek, Katarzyna ; Lubiński, Jan ; Jakubowska, Anna</creatorcontrib><description>Selenium is an essential trace element for humans, playing an important role in various major metabolic pathways. Selenium helps to protect the body from the poisonous effects of heavy metals and other harmful substances. Medical studies have provided evidence of selenium supplementation in preventing certain cancers. Low and too high selenium (Se) status correlates with increased risk of e.g. lung, larynx, colorectal and prostate cancers. A higher level of selenium and supplementation with selenium has been shown to be associated with substantially reduced cancer mortality. Selenium exerts its biological roles through selenoproteins, which are involved in oxidoreductions, redox signalling, antioxidant defence, thyroid hormone metabolism and immune responses. Checkpoint kinase 2 (CHEK2) is an important signal transducer of cellular responses to DNA damage and acts as a tumour suppressor gene. Mutations in the CHEK2 gene have been shown to be associated with increased risks of several cancers. Four common mutations in CHEK2 gene (1100delC, IVS2+1G&gt;A, del5395 and I157T) have been identified in the Polish population. Studies have provided evidence that CHEK2-truncating and/or missense mutations are associated with increased risk of breast, prostate, thyroid, colon and kidney cancers. The variability in penetrance and cancer expression in CHEK2 mutation carriers can probably be explained by the influence of other genetic or environmental factors. One of the possible candidates is Se, which together with genetic variations in selenoprotein genes may influence susceptibility to cancer risk.</description><identifier>ISSN: 0267-8357</identifier><identifier>EISSN: 1464-3804</identifier><identifier>DOI: 10.1093/mutage/get050</identifier><identifier>PMID: 24106007</identifier><language>eng</language><publisher>UK: Oxford University Press</publisher><subject>Checkpoint Kinase 2 - genetics ; Checkpoint Kinase 2 - metabolism ; Dietary Supplements ; Humans ; Mutation ; Neoplasms - enzymology ; Neoplasms - genetics ; Neoplasms - prevention &amp; control ; Selenium - administration &amp; dosage ; Selenium - physiology ; Selenoproteins - metabolism ; Signal Transduction</subject><ispartof>Mutagenesis, 2013-11, Vol.28 (6), p.625-629</ispartof><rights>The Author 2013. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3</citedby><cites>FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24106007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, Satish</creatorcontrib><creatorcontrib>Jaworska-Bieniek, Katarzyna</creatorcontrib><creatorcontrib>Lubiński, Jan</creatorcontrib><creatorcontrib>Jakubowska, Anna</creatorcontrib><title>Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?</title><title>Mutagenesis</title><addtitle>MUTAGE</addtitle><addtitle>Mutagenesis</addtitle><description>Selenium is an essential trace element for humans, playing an important role in various major metabolic pathways. Selenium helps to protect the body from the poisonous effects of heavy metals and other harmful substances. Medical studies have provided evidence of selenium supplementation in preventing certain cancers. Low and too high selenium (Se) status correlates with increased risk of e.g. lung, larynx, colorectal and prostate cancers. A higher level of selenium and supplementation with selenium has been shown to be associated with substantially reduced cancer mortality. Selenium exerts its biological roles through selenoproteins, which are involved in oxidoreductions, redox signalling, antioxidant defence, thyroid hormone metabolism and immune responses. Checkpoint kinase 2 (CHEK2) is an important signal transducer of cellular responses to DNA damage and acts as a tumour suppressor gene. Mutations in the CHEK2 gene have been shown to be associated with increased risks of several cancers. Four common mutations in CHEK2 gene (1100delC, IVS2+1G&gt;A, del5395 and I157T) have been identified in the Polish population. Studies have provided evidence that CHEK2-truncating and/or missense mutations are associated with increased risk of breast, prostate, thyroid, colon and kidney cancers. The variability in penetrance and cancer expression in CHEK2 mutation carriers can probably be explained by the influence of other genetic or environmental factors. One of the possible candidates is Se, which together with genetic variations in selenoprotein genes may influence susceptibility to cancer risk.</description><subject>Checkpoint Kinase 2 - genetics</subject><subject>Checkpoint Kinase 2 - metabolism</subject><subject>Dietary Supplements</subject><subject>Humans</subject><subject>Mutation</subject><subject>Neoplasms - enzymology</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - prevention &amp; control</subject><subject>Selenium - administration &amp; dosage</subject><subject>Selenium - physiology</subject><subject>Selenoproteins - metabolism</subject><subject>Signal Transduction</subject><issn>0267-8357</issn><issn>1464-3804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkD1PwzAURS0EoqUwsiKPLKHP38mEUFQoohILzJGT2JUhiYudDPz7pkqBkek96R7dKx2ErgncEcjYsh16vTXLrelBwAmaEy55wlLgp2gOVKokZULN0EWMHwBEUQnnaEY5AQmg5miV6w5H05jODS0uDda49bWzzgTsLa50V41fcPETuw7n69ULxYfJ3vluTEMYwXh_ic6sbqK5Ot4Fen9cveXrZPP69Jw_bJKKiaxPjKrLkhOiM6ZLbtJaU8mrGkimKqtVSaxIpbSCq5pxRQkXlo2pyEpdp5RatkC3U-8u-K_BxL5oXaxM0-jO-CEWhGdUUuCCjWgyoVXwMQZji11wrQ7fBYHiYK6YzBWTuZG_OVYPZWvqX_pH1d-2H3b_dO0BInh35Q</recordid><startdate>201311</startdate><enddate>201311</enddate><creator>Gupta, Satish</creator><creator>Jaworska-Bieniek, Katarzyna</creator><creator>Lubiński, Jan</creator><creator>Jakubowska, Anna</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U1</scope><scope>7U2</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201311</creationdate><title>Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?</title><author>Gupta, Satish ; Jaworska-Bieniek, Katarzyna ; Lubiński, Jan ; Jakubowska, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Checkpoint Kinase 2 - genetics</topic><topic>Checkpoint Kinase 2 - metabolism</topic><topic>Dietary Supplements</topic><topic>Humans</topic><topic>Mutation</topic><topic>Neoplasms - enzymology</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - prevention &amp; control</topic><topic>Selenium - administration &amp; dosage</topic><topic>Selenium - physiology</topic><topic>Selenoproteins - metabolism</topic><topic>Signal Transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Satish</creatorcontrib><creatorcontrib>Jaworska-Bieniek, Katarzyna</creatorcontrib><creatorcontrib>Lubiński, Jan</creatorcontrib><creatorcontrib>Jakubowska, Anna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Mutagenesis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Satish</au><au>Jaworska-Bieniek, Katarzyna</au><au>Lubiński, Jan</au><au>Jakubowska, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?</atitle><jtitle>Mutagenesis</jtitle><stitle>MUTAGE</stitle><addtitle>Mutagenesis</addtitle><date>2013-11</date><risdate>2013</risdate><volume>28</volume><issue>6</issue><spage>625</spage><epage>629</epage><pages>625-629</pages><issn>0267-8357</issn><eissn>1464-3804</eissn><abstract>Selenium is an essential trace element for humans, playing an important role in various major metabolic pathways. Selenium helps to protect the body from the poisonous effects of heavy metals and other harmful substances. Medical studies have provided evidence of selenium supplementation in preventing certain cancers. Low and too high selenium (Se) status correlates with increased risk of e.g. lung, larynx, colorectal and prostate cancers. A higher level of selenium and supplementation with selenium has been shown to be associated with substantially reduced cancer mortality. Selenium exerts its biological roles through selenoproteins, which are involved in oxidoreductions, redox signalling, antioxidant defence, thyroid hormone metabolism and immune responses. Checkpoint kinase 2 (CHEK2) is an important signal transducer of cellular responses to DNA damage and acts as a tumour suppressor gene. Mutations in the CHEK2 gene have been shown to be associated with increased risks of several cancers. Four common mutations in CHEK2 gene (1100delC, IVS2+1G&gt;A, del5395 and I157T) have been identified in the Polish population. Studies have provided evidence that CHEK2-truncating and/or missense mutations are associated with increased risk of breast, prostate, thyroid, colon and kidney cancers. The variability in penetrance and cancer expression in CHEK2 mutation carriers can probably be explained by the influence of other genetic or environmental factors. One of the possible candidates is Se, which together with genetic variations in selenoprotein genes may influence susceptibility to cancer risk.</abstract><cop>UK</cop><pub>Oxford University Press</pub><pmid>24106007</pmid><doi>10.1093/mutage/get050</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0267-8357
ispartof Mutagenesis, 2013-11, Vol.28 (6), p.625-629
issn 0267-8357
1464-3804
language eng
recordid cdi_proquest_miscellaneous_1492620453
source Oxford Journals Online
subjects Checkpoint Kinase 2 - genetics
Checkpoint Kinase 2 - metabolism
Dietary Supplements
Humans
Mutation
Neoplasms - enzymology
Neoplasms - genetics
Neoplasms - prevention & control
Selenium - administration & dosage
Selenium - physiology
Selenoproteins - metabolism
Signal Transduction
title Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T18%3A15%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Can%20selenium%20be%20a%20modifier%20of%20cancer%20risk%20in%20CHEK2%20mutation%20carriers?&rft.jtitle=Mutagenesis&rft.au=Gupta,%20Satish&rft.date=2013-11&rft.volume=28&rft.issue=6&rft.spage=625&rft.epage=629&rft.pages=625-629&rft.issn=0267-8357&rft.eissn=1464-3804&rft_id=info:doi/10.1093/mutage/get050&rft_dat=%3Cproquest_cross%3E1492620453%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c359t-e7dbb411a93ab4e8da264cd0197cfa7b1f5866f547d3472145f3d0159bad822f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1492620453&rft_id=info:pmid/24106007&rft_oup_id=10.1093/mutage/get050&rfr_iscdi=true